These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 1379967

  • 1. Pharmacokinetic considerations on Orgaran (Org 10172) therapy.
    Danhof M, de Boer A, Magnani HN, Stiekema JC.
    Haemostasis; 1992; 22(2):73-84. PubMed ID: 1379967
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.
    Stiekema JC, Wijnand HP, Van Dinther TG, Moelker HC, Dawes J, Vinchenzo A, Toeberich H.
    Br J Clin Pharmacol; 1989 Jan; 27(1):39-48. PubMed ID: 2468354
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt.
    Vogel GM, van Amsterdam RG, Kop WJ, Meuleman DG.
    Thromb Haemost; 1993 Jan 11; 69(1):29-34. PubMed ID: 8446935
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. ANZ-Organon Investigators' Group.
    Gallus A, Cade J, Ockelford P, Hepburn S, Maas M, Magnani H, Bucknall T, Stevens J, Porteous F.
    Thromb Haemost; 1993 Oct 18; 70(4):562-7. PubMed ID: 7509509
    [Abstract] [Full Text] [Related]

  • 10. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172).
    Magnani HN.
    Thromb Haemost; 1993 Oct 18; 70(4):554-61. PubMed ID: 7509508
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma.
    Zammit A, Dawes J.
    Thromb Haemost; 1994 Jun 18; 71(6):759-67. PubMed ID: 7526481
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin.
    Cantor WJ, Leblanc K, Garvey B, Watson KR, Rasymas A, Strauss BH.
    Catheter Cardiovasc Interv; 1999 Mar 18; 46(3):352-5. PubMed ID: 10348139
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A chronopharmacodynamic study on standard heparin, a low molecular weight heparin (nadroparin) and danaproid: establishing and comparing the daily variations of these drugs in rats.
    Abrial D, Blanc A, Réhailia M, Mismetti P, Bouchut C, Laporte-Simitsidis S, Decousus H, Buisson B.
    Haemostasis; 2000 Mar 18; 30(5):233-42. PubMed ID: 11251330
    [Abstract] [Full Text] [Related]

  • 19. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients.
    ten Cate H, Henny CP, ten Cate JW, Büller HR, Mooy MC, Surachno S, Wilmink JM.
    Thromb Res; 1985 Jul 15; 39(2):211-22. PubMed ID: 3161213
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.